RxDoctor Payments Data

Roberto Martinez, MD

Hematology & Oncology · Oneida, NYNPI 1245308881

Payments from drug & device makers

$11,985in general payments, 2019–2025

Across 411 payments — averaging $29.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$4K
  • Johnson & Johnson$724
  • AstraZeneca$676
  • Novartis$628
  • Merck$529
  • Pfizer$488
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$7,65994%
  • Education$5026%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Takeda Pharmaceuticals U.S.A., Inc.9$3,982
Johnson & Johnson(2 entities)33$724
AstraZeneca(2 entities)36$676
Novartis36$628
Merck23$529
Pfizer24$488
Daiichi Sankyo Inc.15$446
Incyte Corporation17$379
Eisai Inc.15$297
E.r. Squibb & Sons, L.L.C.18$248
AbbVie11$233
Genentech USA, Inc.13$224
Amgen10$212
Lilly USA, LLC12$202
EMD Serono, Inc.10$186
Regeneron Healthcare Solutions, Inc.8$180
Seagen Inc.5$162
Bayer7$158
Astellas Pharma US Inc7$141
Puma Biotechnology, Inc.8$133
Bristol Myers Squibb9$131
Gilead(2 entities)6$94
GSK5$92
Blueprint Medicines Corporation3$80
Karyopharm Therapeutics Inc.4$73
Taiho Oncology, Inc.3$67
Genmab U.S., Inc.3$67
Pharmacosmos Therapeutics Inc.3$66
Array Biopharma Inc5$65
Tersera Therapeutics LLC3$63
Adaptive Biotechnologies Corporation2$63
Ipsen Biopharmaceuticals, Inc3$62
Jazz Pharmaceuticals Inc.3$60
Sanofi3$59
Pharmacyclics LLC, An Abbvie Company3$59
Sobi, Inc3$57
Telix Pharmaceuticals3$56
Springworks Therapeutics, Inc.3$47
Mirati Therapeutics, Inc.2$42
Myriad Genetic Laboratories, Inc.2$36
Novocure Inc.2$35
Exelixis Inc.2$34
ADC Therapeutics America, Inc.2$34
Geron Corporation1$31
Immunogen, Inc.1$26
Foundation Medicine, Inc.1$24
Beigene USA, Inc.1$22
Stemline Therapeutics Inc.1$21
Rigel Pharmaceuticals, Inc.1$21
Sumitomo Pharma America, Inc.1$19
Apellis Pharmaceuticals, Inc.1$18
CTI Biopharma Corp.1$17
Agios Pharmaceuticals, Inc.1$17
IBSA Pharma Inc.1$16
Tempus AI, Inc1$16
Beone Medicines USA, Inc.1$14
Fortovia Therapeutics, Inc.1$14
Ferring Pharmaceuticals Inc.1$13
Partner Therapeutics, Inc.1$12
Morphosys, US Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,985 in reported general payments places this provider in the 60th percentile of 967 hematology & oncology providers in New York.

See all hematology & oncology providers in New York

Medicare billing

Part B allowed, 2024
$40,399
Medicare patients
180
Services billed
337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abiraterone Acetate18$161,543
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen15$334
Dexamethasone17$171
Acyclovir22$155
Prednisone33$148
Levofloxacin23$80
Anastrozole20$78

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Oneida

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →